<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Advanced Dermatofibrosarcoma Protuberans Treatment With Imatinib: Experience From a Dedicated Sarcoma Medical Oncology Clinic in India.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Advanced Dermatofibrosarcoma Protuberans Treatment With Imatinib: Experience From a Dedicated Sarcoma Medical Oncology Clinic in India." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/180c/6223511/d7ac33c31e28/JGO.18.00007f1.jpg"/> </div> <div class="text-side"> <h1>Advanced Dermatofibrosarcoma Protuberans Treatment With Imatinib: Experience From a Dedicated Sarcoma Medical Oncology Clinic in India.</h1> <p>(A) Uniform population of spindled tumor cells arranged in a distinct, monotonous, storiform pattern around an inconspicuous vasculature. There is minimal nuclear pleomorphism and only low mitotic activity. (B) Immunohistochemistry performed for CD34 showing diffuse immunopositivity in the tumor cells. (C) Fibrosarcomatous dermatofibrosarcoma protuberans, where the tumor cells are arranged in fascicular architecture and herringbone pattern (loss of storiform pattern), with moderate nuclear pleomorphism and increased mitotic activity. (D) Immunohistochemistry performed for CD34 showing loss of CD34 immunostaining in a case of fibrosarcomatous transformation. H&amp;E, hematoxylin and eosin.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30085879/" target="_blank">30085879</a></p><p>Type: Premalignant/Malignant, Category: Fibrohistiocytic</p>
</div> </div></div></body></html>